stockportfolio.pro
Stocks / BAX vs BMRN
BAX vs BMRN
Baxter International Inc. and BioMarin Pharmaceutical Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Baxter International Inc. (BAX) | BioMarin Pharmaceutical Inc. (BMRN) | |
|---|---|---|
| Market cap | $10.3B | $10.9B |
| Revenue (latest FY) | $11.24B | $3.22B |
| Net income (latest FY) | $-957.00M | $348.90M |
| Revenue growth (5y CAGR) | -0.7% | 11.6% |
| Net margin | -8.5% | 10.8% |
| Return on equity | -15.6% | 5.7% |
| P/E ratio | — | 40.4 |
| Dividend yield | 1.0% | — |
| Profitable years (of last 10) | 7 | 5 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BAX — free Open BMRN — freeFrequently asked questions
Which is bigger, BAX or BMRN?
BioMarin Pharmaceutical Inc. is larger by market capitalization — $10.9B versus $10.3B.
Which grows faster, BAX or BMRN?
Over the last five fiscal years, BioMarin Pharmaceutical Inc. grew revenue faster — 11.6%/yr versus -0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.